Streetbeat News

TMDX

TransMedics Group, Inc.

https://www.transmedics.com

Industry

Medical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Open

88.93

Mkt cap

2.7B

Volume

2.3M

High

88.93

P/E Ratio

91.45

52-wk high

177.37

Low

80.06

Div yield

N/A

52-wk low

66.76

TransMedics Group, Inc. (TMDX) shares surged 23.5% in pre-market trading after reporting Q4 earnings of 12 cents per share, surpassing estimates for a 3 cent loss, and sales of $81.17 million, beating expectations of $68.51 million. The company also issued strong guidance. Other stocks showed significant movement in pre-market trading, with notable gainers including Janux Therapeutics, Inc. (JANX), PubMatic, Inc. (PUBM), and losers like The Aaron's Company, Inc. (AAN), and Unity Software Inc. (U).

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 12:56 pm

Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group (TMDX) and raises the price target from $92 to $105.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:41 pm

In Monday's after-market session, several health care stocks showed significant movement. Janux Therapeutics, ICU Medical, and Galera Therapeutics were among the top gainers, with Janux Therapeutics leading at a 64.2% increase. On the losing end, NRX Pharmaceuticals saw the largest decrease at 20.5%. The movements were largely attributed to the release of Q4 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 9:31 pm

TransMedics shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided strong future guidance.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:24 pm

TransMedics forecasts a significant revenue increase for the full year 2024, expecting total revenue to be between $360M-$370M, which surpasses the estimated $330.227M. This projection indicates a growth of 49% to 53% compared to the previous year's revenue.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:10 pm

TransMedics Gr (NASDAQ:TMDX) reported Q4 earnings of $0.12 per share, surpassing the $(0.03) estimate, marking a 157.14% increase from last year. Sales reached $81.17M, beating the $68.51M estimate, a 158.72% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:08 pm

Surgery Partners reported weak quarterly sales, causing its shares to fall 7.8%. Other stocks like Intuitive Machines, Nyxoah, Jin Medical International, and several others also recorded losses. Notably, Intuitive Machines dropped 25.1% due to a lunar lander incident, and Kosmos Energy saw a 7% decline despite beating revenue expectations.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 4:19 pm

Numerous companies are scheduled to report their earnings on February 26, 2024, covering a wide range of industries from energy to technology. Key reports include Kosmos Energy, Krystal Biotech, Li Auto, and Domino's Pizza, among others. The diversity of sectors represented suggests a comprehensive insight into the economic and business trends affecting these markets.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 9:47 am

TransMedics Gr (NASDAQ:TMDX) is scheduled to release its quarterly earnings report on February 26, 2024, with an expected EPS of $-0.03. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, TransMedics has had a mixed performance in beating EPS estimates, with significant share price movements following the earnings announcements. The stock has seen a 9.52% increase over the last 52 weeks, trading at $84.81 as of February 22.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:01 pm

TransMedics has acquired a fixed-wing aircraft from Munday Aviation, LLC for approximately $13.2M on December 18, 2023, as disclosed in a filing. This acquisition adds to the nine aircraft previously acquired by the company, bringing the total to ten. These aircraft will be used to transport donor organs.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 9:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.